Absence of an interaction between iron and mycophenolate mofetil absorption.
OBJECTIVE
To determine whether concomitant iron affects the absorption of mycophenolate mofetil.


METHODS
An open-label, single centre, randomized, crossover trial was conducted in 16 healthy males. Fasting subjects received mycophenolate mofetil alone (treatment A) or co-administered with iron (treatment B).


RESULTS
The mycophenolic acid AUC(0,24 h) for treatments A and B were 42.5 +/- 10.5 and 44.7 +/- 12.4 microg ml(-1) h, respectively. anova modelling showed the relative bioavailability of mycophenolate mofetil to be similar for the two treatments (90% confidence interval 0.92, 1.19).


CONCLUSIONS
There was no interaction between mycophenolate mofetil and iron supplements administered concomitantly to healthy fasting subjects.
Ducray
Patricia Sanwald
PS
Clinical Pharmacology Department, F. Hoffmann-La Roche Ltd, Basel, Switzerland. patricia.sanwald_ducray@roche.com
Banken
Ludger
L
Gerber
Marianne
M
Boutouyrie
Bruno
B
Zandt
Hagen
H
D000328:Adult; D018592:Cross-Over Studies; D004347:Drug Interactions; D005296:Ferrous Compounds / Q000008:administration & dosage / Q000009:adverse effects*; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage / Q000493:pharmacokinetics*; D007501:Iron; D008297:Male; D009173:Mycophenolic Acid / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000493:pharmacokinetics
D005296:Ferrous Compounds; D007166:Immunosuppressive Agents; D007501:Iron; D009173:Mycophenolic Acid